[1] Yang J D, Hainaut P, Gores G J, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol,2019,16(10): 589-604.
[2] Li W, Deng R, Liu S, et al. Hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy: the emerging role of non-viral risk factors[J]. Liver Int,2020,40(10): 2316-2325.
[3] Castellana M, Donghia R, Lampignano L, et al. Prevalence of the absence of cirrhosis in subjects with NAFLD-associated hepatocellular carcinoma[J]. J Clin Med,2021,10(20): 4638.
[4] 窦晓光,徐小元,南月敏,等.2022年肝脏疾病研究进展[J].中华肝脏病杂志,2023,31(1): 3-15.
[5] Yip T C, Lee H W, Chan W K, et al. Asian perspective on NAFLD-associated HCC[J]. J Hepatol,2022,76(3): 726-734.
[6] Estes C, Anstee Q M, Arias-Loste M T, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016—2030[J]. J Hepatol,2018,69(4): 896-904.
[7] Grgurevic I, Bozin T, Mikus M, et al. Hepatocellular carcinoma in non-alcoholic fatty liver disease: from epidemiology to diagnostic approach[J]. Cancers,2021,13(22): 5844.
[8] Foerster F, Gairing S J, Müller L, et al. NAFLD-driven HCC: safety and efficacy of current and emerging treatment options[J]. J Hepatol,2022,76(2): 446-457.
[9] 杨荣,范建高.非酒精性脂肪性肝病相关肝细胞肝癌的研究进展[J].临床内科杂志,2022,39(12): 793-796.
[10] Pinyol R, Torrecilla S, Wang H, et al. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis[J]. J Hepatol,2021,75(4): 865-878.
[11] Lim G E H, Tang A, Ng C H, et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD[J]. Clin Gastroenterol Hepatol,2023,21(3): 619-629.e7.
[12] Huang D Q, Mathurin P, Cortez-Pinto H, et al. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors[J]. Nat Rev Gastroenterol Hepatol,2023,20(1): 37-49.
[13] Seitz H K, Bataller R, Cortez-Pinto H, et al. Alcoholic liver disease[J]. Nat Rev Dis Primers,2018,4(1): 16.
[14] Mancebo A, González-Diéguez M L, Cadahía V, et al. Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups[J]. Clinical Gastroenterology and Hepatology,2013,11(1): 95-101.
[15] Petrick J L, Campbell P T, Koshiol J, et al. Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the liver cancer pooling project[J]. Br J Cancer,2018,118(7): 1005-1012.
[16] Trépo E, Caruso S, Yang J, et al. Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study[J]. Lancet Oncol,2022,23(1): 161-171.
[17] Buch S, Innes H, Lutz P L, et al. Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study[J]. Gut,2023,72(2): 381-391.
[18] Woodward C, Smith J, Acreman D, et al. Hepatocellular carcinoma in body builders; an emerging rare but serious complication of androgenic anabolic steroid use[J]. Ann Hepatobiliary Pancreat Surg,2019,23(2): 174-177.
[19] Zhang H, Li X X, Yang Y, et al. Significance and mechanism of androgen receptor overexpression and androgen receptor/mechanistic target of rapamycin cross-talk in hepatocellular carcinoma[J]. Hepatology,2018,67(6): 2271-2286.
[20] 雷晓红,李静,唐洁婷,等.EASL临床实践指南简介:药物性肝损伤[J].肝脏,2019,24(04): 339-348.
[21] Khalid S, Laput G, Khorfan K, et al. Development of liver cancers as an unexpected consequence of anabolic androgenic steroid use[J]. Cureus,2023,15(1): e34357.
[22] Chen C J, Yang Y H, Lin M H, et al. Herbal medicine containing aristolochic acid and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection[J]. Int J Cancer,2018,143(7): 1578-1587.
[23] Rigopoulou E I, Dalekos G N. Current Trends and characteristics of hepatocellular carcinoma in patients with autoimmune liver diseases[J]. Cancers,2021,13(5): 1023.
[24] Tansel A, Katz L H, El-Serag H B, et al. Incidence and determinants of hepatocellular carcinoma in autoimmune hepatitis: a systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol,2017,15(8): 1207-1217.e4.
[25] European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis[J]. J Hepatol,2015,63(4): 971-1004.
[26] Yan L J, Yao S Y, Meng G X, et al. Sex and regional disparities in incidence of hepatocellular carcinoma in autoimmune hepatitis: a systematic review and meta-analysis[J]. Hepatol Int,2021,15(6): 1413-1420.
[27] 郭文沛,张海燕,刘立新.自身免疫性肝炎相关肝细胞癌的研究进展[J].临床肝胆病杂志,2022,38(06): 1431-1435.
[28] Mack C L, Adams D, Assis D N, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases[J]. Hepatology,2020,72(2): 671-722.
[29] Ali A H, Tabibian J H, Nasser-Ghodsi N, et al. Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis[J]. Hepatology,2018,67(6): 2338-2351.
[30] Loomba R, Lim J K, Patton H, et al. AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review[J]. Gastroenterology,2020,158(6): 1822-1830.
[31] Best J, Bechmann L P, Sowa J P, et al. GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis[J]. Clin Gastroenterol Hepatol,2020,18(3): 728-735.e4.
[32] Zaki M Y W, Mahdi A K, Patman G L, et al. Key features of the environment promoting liver cancer in the absence of cirrhosis[J]. Sci Rep,2021,11(1): 16727.
[33] Bianvo C, Jamialahmadi O, Pelusi S, et al. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores[J]. J Hepatol,2021,74(4): 775-782.
[34] Heinrich B, Gertz E M, Schäffer A A, et al. The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma[J]. Gut,2022,71(6): 1161-1175.
[35] Leslie J, Mackey J B G, Jamieson T, et al. CXCR2 inhibition enables NASH-HCC immunotherapy[J]. Gut,2022,71(10): 2093-2106.
[36] Shalapour S, Lin X J, Bastian I N, et al. Erratum: inflammation-induced IgA(+) cells dismantle anti-liver cancer immunity[J]. Nature,2017,552(7685): 430.
[37] Llovet J M, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma[J]. Nat Rev Clin Oncol,2022,19(3): 151-172.
[38] Murai H, Kodama T, Maesaka K, et al. Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma[J]. Hepatology,2023,77(1): 77-91.
[39] Pfister D, Núñez N G, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC[J]. Nature,2021,592(7854): 450-456.
[40] Villanueva A. Hepatocellular carcinoma[J]. N Engl J Med,2019,380(15): 1450-1462.
[41] Baumeister S E, Schlesinger S, Aleksandrova K, et al. Association between physical activity and risk of hepatobiliary cancers: a multinational cohort study[J]. J Hepatol,2019,70(5): 885-892.
[42] Kennedy O J, Roderick P, Buchanan R, et al. Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis[J]. BMJ Open,2017,7(5): e013739. |
